Future Science GroupBrowse
Infographic_fon-2021-1006.pdf (2.18 MB)
Download file

Infographic – Summary of the CaboPoint study

Download (2.18 MB)
figure
posted on 2021-12-20, 14:30 authored by Laurence Albiges, Manuela Schmidinger, Naila Taguieva-Pioger, David Perol, Viktor Grünwald, Eric Guemas
CaboPoint: a Phase II study of cabozantinib as second-line treatment in patients with metastatic renal cell carcinoma

Funding

Ipsen

History

Usage metrics

Read the peer-reviewed publication

CaboPoint: a Phase II study of cabozantinib as second-line treatment in patients with metastatic renal cell carcinoma
Future OncologyFuture Oncology

Categories

Keywords

cabozantinibcheckpoint inhibitorrenal cell carcinomasecond linetyrosine kinase inhibitorCancer Therapy (excl. Chemotherapy and Radiation Therapy)

Licence

CC BY-NC-ND 4.0

Exports